Positives

• A caregiver reported their family member with EDS was doing okay on Dilaudid for severe pain control after other regimens failed Inspire.
  
  
• Some EDS patients report that hydromorphone and similar potent opioids are essential for managing severe flares when NSAIDs and lower-tier analgesics fail Ehlers-Danlos Society.
  
  

Negatives

• Patients with hEDS frequently develop worsening constipation, nausea, and gastroparesis on hydromorphone, and the drug can directly trigger MCAS mast cell degranulation PMC.
  
  
• Long-term opioid use in hEDS patients risks central pain sensitization, which can paradoxically worsen baseline pain over time Wiley.
  
  

Hurdles & Side Effects

• Patients describe being labeled drug-seeking when requesting hydromorphone for documented EDS pain, leading to undertreatment in ER and inpatient settings PMC.
  
  
• Post-CDC-guideline tapering has made it nearly impossible for many EDS patients to find a pain physician willing to continue Schedule II opioids long-term Ehlers-Danlos Society.